Literature DB >> 11403356

Vascular expression of angiotensin type 2 receptor in the adult rat: influence of angiotensin II infusion.

F Bonnet1, M E Cooper, R M Carey, D Casley, Z Cao.   

Abstract

OBJECTIVE: The aim of this study was to investigate the relative role of the angiotensin type 1 (AT1) and type 2 (AT2) receptors in mediating angiotensin II-induced regulation of AT2 receptor in mesenteric artery.
DESIGN: Sprague-Dawley rats were infused with either angiotensin II or vehicle for 14 days at a dose of 58.3 ng/min. Ang II-infused rats were allocated to receive either an AT1 antagonist, valsartan at a dose of 30 mg/kg per day or the AT2 receptor antagonist PD123319 at a dose of 830 ng/min.
METHODS: Gene and protein expression of the AT2 receptor in the mesenteric vasculature was assessed by quantitative reverse transcriptase polymerase chain reaction, immunohistochemistry and by in vitro autoradiography with a specific radioligand, 1251-CGP 42112B.
RESULTS: The AT2 receptor mRNA and protein were detected in the mesenteric artery from adult rats. Both nuclear emulsion and immunohistochemical staining showed expression of the AT2 receptor in the adventitial and medial layers. Compared to control rats, angiotensin II infusion was associated with a significant increase in the AT2 receptor expression. Valsartan treatment significantly reduced AT2 receptor gene expression, with no significant effect of PD123319 on this parameter.
CONCLUSIONS: This study confirms that the presence of the AT2 receptor in mesenteric arteries in adult rats, shows an up-regulation of the AT2 receptor following angiotensin II infusion and suggests a role for the AT1 receptor in this regulation. In view of the recently demonstrated effects of the AT2 receptor, these findings may be relevant to the role of the AT2 receptor in the pathophysiology of vascular remodeling.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11403356     DOI: 10.1097/00004872-200106000-00012

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  8 in total

Review 1.  Angiotensin AT2 receptors: cardiovascular hope or hype?

Authors:  Robert E Widdop; Emma S Jones; Ruth E Hannan; Tracey A Gaspari
Journal:  Br J Pharmacol       Date:  2003-10-06       Impact factor: 8.739

2.  High blood pressure reduction reverses angiotensin II type 2 receptor-mediated vasoconstriction into vasodilation in spontaneously hypertensive rats.

Authors:  Dong You; Laurent Loufrani; Celine Baron; Bernard I Levy; Robert E Widdop; Daniel Henrion
Journal:  Circulation       Date:  2005-02-14       Impact factor: 29.690

Review 3.  Understanding the Two Faces of Low-Salt Intake.

Authors:  Branko Braam; Xiaohua Huang; William A Cupples; Shereen M Hamza
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

4.  AT2 receptor-mediated vasodilatation is unmasked by AT1 receptor blockade in conscious SHR.

Authors:  Xiao C Li; Robert E Widdop
Journal:  Br J Pharmacol       Date:  2004-06-14       Impact factor: 8.739

Review 5.  The intrarenal renin-angiotensin and dopaminergic systems: control of renal sodium excretion and blood pressure.

Authors:  Robert M Carey
Journal:  Hypertension       Date:  2013-03       Impact factor: 10.190

Review 6.  AT2 receptors: beneficial counter-regulatory role in cardiovascular and renal function.

Authors:  Shetal H Padia; Robert M Carey
Journal:  Pflugers Arch       Date:  2012-09-05       Impact factor: 3.657

7.  Renoprotective effects of telmisartan after unilateral renal ablation in rats.

Authors:  Tomohiro Matsuo; Yasuyoshi Miyata; Yuji Sagara; Yoshikazu Higami; Shohei Tobu; Manabu Matsuo; Mitsuru Noguchi; Isao Shimokawa; Hiroshi Kanetake; Hideki Sakai
Journal:  Int J Nephrol Renovasc Dis       Date:  2013-10-10

8.  Modulation of haemodynamics, endogeneous antioxidant enzymes, and pathophysiological changes by selective inhibition of angiotensin II type 1 receptors in pressureoverload rats.

Authors:  Ghulam Moinuddin; Mohammed Naseeruddin Inamdar; Kala S Kulkarni; Chanda Kulkarni
Journal:  Cardiovasc J Afr       Date:  2013-04       Impact factor: 1.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.